Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer.

ABSTRACT:

Background

This study aimed to investigate the efficacy and safety of cytokine-induced killer (CIK)/dendritic cell combined with CIK (DC-CIK) cell therapy in advanced gastrointestinal cancer (GIC).

Methods

The PubMed, Cochrane library, and Embase were searched to conduct a meta-analysis of clinical controlled trials to evaluate the efficacy and safety of CIK/DC-CIK cell therapy in advanced GIC. The pooled risk ratios (RRs) or weighted mean difference (WMD) with 95% confidence intervals (95% CIs) were calculated.

Results

A total of nine studies with 1113 patients were identified. The overall survival (RR?=?1.84, 95% CI?=?1.41-2.40, P_{heterogeneity}?=?0.654, I²?=?0%), progression-free survival (RR?=?1.99, 95% CI?=?1.52-2.60, P_{heterogeneity}?=?0.727, I²?=?0%), and quality of life (WMD?=?16.09, 95% CI?=?1.66-30.52, P_{heterogeneity}?2?=?98.8%) were significantly improved in patients who received chemotherapy combined with CIK/DC-CIK cells, and no severe adverse events were reported.

Conclusion

This meta-analysis suggested that the combination of CIK/DC-CIK immunotherapy and chemotherapy was safe and applicable for patients with advanced GIC. It is a feasible choice to prolong survival and improve quality of life.

SUBMITTER: Du H 

PROVIDER: S-EPMC7189715 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature